Hagiwara A, Ahn T, Ueda T, Iwamoto A, Ueda T, Torii T, Takahashi T
Anticancer Res. 1986 Sep-Oct;6(5):1005-8.
A new dosage form consisting of small activated carbon particles which adsorb Aclacinomycin A, Adriamycin, Mitomycin C or Pepleomycin was prepared in order to deliver larger amounts of anticancer agents to the lymph nodes through the high ability of lymphatics to adsorb particles. Animal experiments showed that: The LD50 values of the new dosage form were higher than those of the dosage in solution. The concentration of agents in lymph nodes was maintained at a higher level in the new dosage form than in solution form. Clinically 33% of lymphnodal metastatic lesions became degenerative or inflammatory after a single administration.
制备了一种由吸附阿克拉霉素A、阿霉素、丝裂霉素C或博来霉素的小活性炭颗粒组成的新剂型，以便通过淋巴管吸附颗粒的高能力将大量抗癌剂输送到淋巴结。动物实验表明：新剂型的半数致死量值高于溶液剂型。新剂型中淋巴结内药物浓度比溶液剂型维持在更高水平。临床上，单次给药后33%的淋巴结转移病变发生退变或炎症。
